Valneva SE

NASDAQ:VALN

Biotechnology

Healthcare
$5.34 +0.19%

+$0.01 today

Market cap
$507.98M
Beta
1.40
P/E (TTM)
-2.9
EPS (TTM)
-$0.80
52W Low $5.06High $12.25

Volume 0.00M

Average 0.09M

VALN Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Valneva SENASDAQ: VALN

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses declines year over year

Q1 FY2026 operating expenses of €28.42M fell 11.6% year over year, behind the -1.4% change in trailing-twelve-month operating expenses. Sequentially, it fell 27.7% from the prior quarter. Over 3 fiscal years it compounded at -0.3% a year.

Context

  • Operating expenses amounted to 85.4% of revenue in FY2025, up 51.4 pp from a year earlier.
  • Operating expenses increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -11.6% toward the trailing-twelve-month pace of -1.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
€28.42M-27.7% QoQ
Last fiscal yearDec 2025
€149.15M+158.4% YoY
LTMMar 2026
€145.42M-1.4% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-11.6%——
1 year+158.4%——
3-year CAGR-0.3%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

EUR · from the income statement

Latest · FY2025
149.15M EUR
Year-over-year change
+158.4%
4-year CAGR
-9.4%

Operating Expenses vs competitors

How VALN compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -1.4% is the 4th highest of 8, against a peer median of -2.4%.
  • Operating expenses amounts to 93.0% of revenue for VALN, versus a peer median of 246.8%.
VALN Competitors
Operating Expenses for VALN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MRNAModerna, Inc.LTM Sep 2026$3.64B USD-2.4%+0.9%144.0%
PCVXVaxcyte, Inc.LTM Jun 2026$1.16B USD+65.4%+58.4%—
VIRVir Biotechnology, Inc.LTM Mar 2026$641.93M USD+299.5%+48.0%980.1%
NVAXNovavax, Inc.LTM Mar 2026$571.48M USD-16.7%-28.6%95.8%
IBRXImmunityBio, Inc.LTM Sep 2026$450.66M USD+32.9%+1.6%246.8%
VALNValneva SELTM Mar 2026€145.42M EUR-1.4%-0.3%93.0%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$130.57M USD-39.9%-10.4%287.9%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$81.48M USD-22.1%-32.1%—
Peer median (excluding VALN) —-2.4%+0.9%246.8%

Competitors are the stored peer set for VALN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue348.09M361.3M153.71M169.58M174.66M
Cost of Revenue187.92M324.44M100.88M98.54M107.14M
Gross Profit160.17M36.86M52.84M71.04M67.52M
Gross Margin46.0%10.2%34.4%41.9%38.7%
Research & Development173.28M104.92M59.89M74.14M85.3M
Selling, General & Admin71.25M57.58M96.55M95.11M74.68M
Operating Expenses221.56M150.31M134.92M57.71M149.15M
Depreciation & Amortization14.28M21.04M17.58M19.59M21.75M
EBITDA(38.74M)(104.73M)(57.72M)32.08M(50.47M)
EBITDA Margin-11.1%-29.0%-37.6%18.9%-28.9%
Operating Income(61.39M)(113.44M)(82.09M)13.33M(81.63M)
Operating Margin-17.6%-31.4%-53.4%7.9%-46.7%
Interest Income249K260K1.21M2.36M1.8M
Interest Expense16.96M19.05M23.33M23.98M41.9M
Other Income / Expenses(8.59M)(31.37M)(16.54M)(24.82M)(32.49M)
Income Before Tax(69.98M)(144.82M)(98.63M)(11.49M)(114.12M)
Pre-Tax Margin-20.1%-40.1%-64.2%-6.8%-65.3%
Income Tax Expense3.45M(1.54M)2.8M761K1.07M
Net Income(73.43M)(143.28M)(101.43M)(12.25M)(115.19M)
Net Margin-21.1%-39.7%-66.0%-7.2%-66.0%
EPS (Basic)(1.50)(2.48)(1.46)(0.17)(1.32)
EPS (Diluted)(1.50)(2.48)(1.46)(0.17)(1.32)
Weighted Avg Shares48.81M57.74M69.47M70.26M84.09M
Weighted Avg Shares (Diluted)48.81M57.74M69.31M70.26M84.09M

Valneva SE

NASDAQ:VALN

Intrinsic Alpha fair value

Locked

Current Price

$5.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.